valproic acid has been researched along with Day Blindness in 13 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
| Excerpt | Relevance | Reference |
|---|---|---|
| "To evaluate the potential efficacy and assess the safety of orally administered valproic acid (VPA) in the treatment of autosomal dominant retinitis pigmentosa." | 9.27 | Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial. ( Bernstein, PS; Birch, DG; Bramer, S; Chegarnov, E; Csaky, K; Erker, L; Fish, GE; Francis, PJ; Hartnett, ME; Heckenlively, J; Hughbanks-Wheaton, DK; Iannacone, A; Jayasundera, T; Lam, BL; Lindblad, R; McCormack, J; Pennesi, ME; Rose, S; Sklaver, NL; Smith, T; Teske, MP; VanVeldhuisen, PC; Wahle, A; Warner, J; Weleber, RG; Winthrop, KL; Yang, P; Zilliox, P, 2018) |
| "To evaluate the potential efficacy and assess the safety of orally administered valproic acid (VPA) in the treatment of autosomal dominant retinitis pigmentosa." | 5.27 | Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial. ( Bernstein, PS; Birch, DG; Bramer, S; Chegarnov, E; Csaky, K; Erker, L; Fish, GE; Francis, PJ; Hartnett, ME; Heckenlively, J; Hughbanks-Wheaton, DK; Iannacone, A; Jayasundera, T; Lam, BL; Lindblad, R; McCormack, J; Pennesi, ME; Rose, S; Sklaver, NL; Smith, T; Teske, MP; VanVeldhuisen, PC; Wahle, A; Warner, J; Weleber, RG; Winthrop, KL; Yang, P; Zilliox, P, 2018) |
| " Eighty patients presenting with epilepsy received monotherapies of valproic acid, phenytoin, or carbamazepine; 18 patients did not receive antiepileptic drug therapy." | 3.69 | Color vision tests for early detection of antiepileptic drug toxicity. ( Bayer, AU; Dichgans, J; Kuehn, M; Paulus, W; Ried, S; Schmidt, D; Thiel, HJ; Zrenner, E, 1997) |
| "The use of VPA in the treatment of epilepsy is not associated with visual field defects similar to vigabatrin, but may induce abnormalities in colour vision." | 2.71 | Visual function in epilepsy patients treated with initial valproate monotherapy. ( Kälviäinen, R; Mäntyjärvi, M; Rissanen, E; Sorri, I, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Androsova, G | 1 |
| Krause, R | 1 |
| Borghei, M | 1 |
| Wassenaar, M | 1 |
| Auce, P | 1 |
| Avbersek, A | 1 |
| Becker, F | 1 |
| Berghuis, B | 1 |
| Campbell, E | 1 |
| Coppola, A | 1 |
| Francis, B | 1 |
| Wolking, S | 1 |
| Cavalleri, GL | 1 |
| Craig, J | 1 |
| Delanty, N | 1 |
| Koeleman, BPC | 1 |
| Kunz, WS | 1 |
| Lerche, H | 1 |
| Marson, AG | 1 |
| Sander, JW | 1 |
| Sills, GJ | 1 |
| Striano, P | 1 |
| Zara, F | 1 |
| Sisodiya, SM | 1 |
| Depondt, C | 1 |
| Birch, DG | 1 |
| Bernstein, PS | 1 |
| Iannacone, A | 1 |
| Pennesi, ME | 1 |
| Lam, BL | 1 |
| Heckenlively, J | 1 |
| Csaky, K | 1 |
| Hartnett, ME | 1 |
| Winthrop, KL | 1 |
| Jayasundera, T | 1 |
| Hughbanks-Wheaton, DK | 1 |
| Warner, J | 1 |
| Yang, P | 1 |
| Fish, GE | 1 |
| Teske, MP | 1 |
| Sklaver, NL | 1 |
| Erker, L | 1 |
| Chegarnov, E | 1 |
| Smith, T | 1 |
| Wahle, A | 1 |
| VanVeldhuisen, PC | 1 |
| McCormack, J | 1 |
| Lindblad, R | 1 |
| Bramer, S | 1 |
| Rose, S | 1 |
| Zilliox, P | 1 |
| Francis, PJ | 1 |
| Weleber, RG | 1 |
| Brooks, BP | 1 |
| Jeffrey, B | 1 |
| James, EJ | 1 |
| Gu, J | 1 |
| Ramirez-Vizcarrondo, CM | 1 |
| Hasan, M | 1 |
| Truszkowski, TL | 1 |
| Tan, Y | 1 |
| Oupravanh, PM | 1 |
| Khakhalin, AS | 1 |
| Aizenman, CD | 1 |
| Oppenheim, C | 1 |
| Touzé, E | 1 |
| Meder, JF | 1 |
| Shahar, E | 1 |
| Ravid, S | 1 |
| Andraus, J | 1 |
| Sorri, I | 1 |
| Rissanen, E | 1 |
| Mäntyjärvi, M | 1 |
| Kälviäinen, R | 1 |
| Wild, JM | 1 |
| Robson, CR | 1 |
| Jones, AL | 1 |
| Cunliffe, IA | 1 |
| Smith, PE | 1 |
| Tilz, C | 1 |
| Wang-Tilz, Y | 1 |
| Jünemann, A | 1 |
| Stefan, H | 1 |
| Michelson, G | 1 |
| Bayer, AU | 1 |
| Thiel, HJ | 1 |
| Zrenner, E | 1 |
| Dichgans, J | 1 |
| Kuehn, M | 1 |
| Paulus, W | 1 |
| Ried, S | 1 |
| Schmidt, D | 1 |
| Ruether, K | 1 |
| Pung, T | 1 |
| Kellner, U | 1 |
| Schmitz, B | 1 |
| Hartmann, C | 1 |
| Seeliger, M | 1 |
| Jung, P | 1 |
| Doussard-Lefaucheux, S | 1 |
| Ozkul, Y | 1 |
| Gurler, B | 1 |
| Uckardes, A | 1 |
| Bozlar, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Multiple Site, Randomized, Placebo-Controlled Trial of Oral Valproic Acid for Autosomal Dominant Retinitis Pigmentosa[NCT01233609] | Phase 2 | 90 participants (Actual) | Interventional | 2010-11-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Mean change in best corrected visual acuity as assessed by ETDRS (Early Treatment Diabetic Retinopathy Study) method from baseline to week 52 (NCT01233609)
Timeframe: baseline to week 52
| Intervention | letters read correctly (Mean) |
|---|---|
| Valproic Acid -- Right Eye | -1.4 |
| Valproic Acid--Left Eye | 0.0 |
| Placebo --Right Eye | 0.2 |
| Placebo --Left Eye | 1.3 |
Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the I4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model (NCT01233609)
Timeframe: baseline to week 52
| Intervention | Visual field area (degrees squared) (Mean) |
|---|---|
| Placebo--Right Eye | 80.9 |
| Placebo--Left Eye | 115.7 |
| Valproic Acid--Right Eye | 5.3 |
| Valproic Acid--Left Eye | 19.5 |
Mean change in visual field area from baseline to 52 weeks. Visual field area is measured with semi-automated kinetic perimetry (SKP) using the Octopus 900 (Haag-Streit) with the III4e target size for each eye and done at least twice to ensure reliable sessions; the visual field area measurements are averaged over the two sessions. Analysis performed with linear mixed model (NCT01233609)
Timeframe: baseline to week 52
| Intervention | Visual field area (degrees squared) (Mean) |
|---|---|
| Placebo--Right Eye | -122.9 |
| Placebo--Left Eye | -112.0 |
| Valproic Acid--Right Eye | -293.7 |
| Valproic Acid--Left Eye | -237.1 |
Mean change from baseline at week 52 for Full field Hill of Vision (Static perimetry) (NCT01233609)
Timeframe: baseline to week 52
| Intervention | db-steridians (Mean) |
|---|---|
| Placebo--Right Eye | -0.3 |
| Placebo--Left Eye | -1.4 |
| Valproic Acid--Right Eye | -0.2 |
| Valproic Acid--Left Eye | -0.6 |
Mean Change from baseline to week 52 for Static Perimetry Volume --30 Degree Hill of Vision. Full field static perimetry protocol was followed using the Octopus 900 (Haag-Streit) for a single session for each eye. (NCT01233609)
Timeframe: baseline to week 52
| Intervention | db-steridans (Mean) |
|---|---|
| Placebo--Right Eye | -0.3 |
| Placebo--Left Eye | -0.3 |
| Valproic Acid--Right Eye | -0.2 |
| Valproic Acid--Left Eye | -0.2 |
2 trials available for valproic acid and Day Blindness
| Article | Year |
|---|---|
Effect of Oral Valproic Acid vs Placebo for Vision Loss in Patients With Autosomal Dominant Retinitis Pigmentosa: A Randomized Phase 2 Multicenter Placebo-Controlled Clinical Trial.
Topics: Administration, Oral; Adult; Aged; Anticonvulsants; Double-Blind Method; Electroretinography; Female | 2018 |
Visual function in epilepsy patients treated with initial valproate monotherapy.
Topics: Adult; Aged; Anticonvulsants; Color Perception; Contrast Sensitivity; Epilepsy; Female; Functional L | 2005 |
11 other studies available for valproic acid and Day Blindness
| Article | Year |
|---|---|
Comparative effectiveness of antiepileptic drugs in patients with mesial temporal lobe epilepsy with hippocampal sclerosis.
Topics: Adolescent; Adult; Aged; Amines; Anticonvulsants; Ataxia; Benzodiazepines; Carbamazepine; Clobazam; | 2017 |
Methodological Insights for Randomized Clinical Trials of Retinitis Pigmentosa: Lessons Learned From a Trial of Valproic Acid.
Topics: Blindness; Humans; Randomized Controlled Trials as Topic; Retinitis Pigmentosa; Valproic Acid; Visio | 2018 |
Valproate-induced neurodevelopmental deficits in Xenopus laevis tadpoles.
Topics: Animals; Animals, Genetically Modified; Anticonvulsants; Avoidance Learning; Convulsants; Dendrites; | 2015 |
[Case no 3. MELAS syndrome].
Topics: Adolescent; Diagnosis, Differential; GABA Agents; Headache; Humans; Magnetic Resonance Imaging; Male | 2003 |
[Childhood-onset epileptic blindness--clinical correlates and outcomes].
Topics: Age of Onset; Anticonvulsants; Blindness; Carbamazepine; Child; Epilepsy; Follow-Up Studies; Humans; | 2004 |
Detecting vigabatrin toxicity by imaging of the retinal nerve fiber layer.
Topics: Adult; Anticonvulsants; Carbamazepine; Cross-Sectional Studies; Epilepsy; Female; Humans; Male; Nerv | 2006 |
Visual field defect during therapy with valproic-acid.
Topics: Adult; Epilepsy; Female; GABA Agents; gamma-Aminobutyric Acid; Humans; Retina; Retinal Degeneration; | 2007 |
Color vision tests for early detection of antiepileptic drug toxicity.
Topics: Adolescent; Adult; Anticonvulsants; Carbamazepine; Color Perception; Epilepsy; Humans; Osmolar Conce | 1997 |
Electrophysiologic evaluation of a patient with peripheral visual field contraction associated with vigabatrin.
Topics: Adolescent; Anticonvulsants; Electroretinography; Epilepsies, Partial; gamma-Aminobutyric Acid; Huma | 1998 |
[Visual field defect in a patient given sodium valporate then carbamazepine: possible effect of aminotransferase inhibition].
Topics: Adult; Amino Acid Metabolism, Inborn Errors; Anticonvulsants; Carbamazepine; Drug Therapy, Combinati | 2002 |
Visual functions in epilepsy patients on valproate monotherapy.
Topics: Adolescent; Adult; Anticonvulsants; Electroretinography; Epilepsy; Female; Humans; Male; Reference V | 2002 |